[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548112":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":47,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":74,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Ospedale San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with acute or chronic nephropathy",null,"1. Patients with chronic nephropathies\n2. Patients with acute nephropathy\n3. Patients with nephrectomy\n4. Candidate Patients to major surgery\n5. Patients with decompensated heart failure undergoing either medical or surgical therapy\n6. Acute critically ill patients (e.g sepsis, post-operative)\n7. Patients with hypertension\n8. Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation.\n9. Long-term surviving patients who received bone marrow transplantation.",[13],"Genetic: genetic polymorphisms",[15],{"type":16,"name":17,"description":10,"armGroupLabels":18,"otherNames":10},"GENETIC","genetic polymorphisms",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Chiara Livia Lanzani, prof","CONTACT","+393408163279","lanzani.chiara@hsr.it",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Laura Zagato, biologist","+390226435745","zagato.laura@hsr.it",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"IRCCS Ospedale San Raffaele","RECRUITING","Milan","20132","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],9.18951,45.46427,{"lat":41,"lon":40},[44],{"name":45,"role":22,"phone":46,"phoneExt":10,"email":24},"Chiara Lanzani, MD","+390226433891",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chiara Lanzani","Clinical Assistant","100548112","genetics-in-the-progression-of-nephropathies-100548112",false,"NCT06416761","Genetics in the Progression of Nephropathies","The Genetic Contribution to Progression of Kidney Disease","Inclusion Criteria:\n\n. presence of specific renal disease\n\nExclusion Criteria:\n\n* to be evaluated in the different sub-protocols","ALL","18 Years",{"count":61,"type":62},10000,"ESTIMATED","OBSERVATIONAL","This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to:\n\n* AKI\n* CKD\n* Hypertension\n* ADPKD\n* CKD-MBD\n* Patients with decompensated heart failure undergoing either medical or surgery therapy\n* Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation\n* glomerular diseases",[66,67,68,69,70,71,72,73],"AKI","CKD","Ckd-Mbd","CKD (Chronic Kidney Disease) Stage 5D","ADPKD","Hypertension","Hematologic Malignancy","Bone Marrow Transplant Complications",[75,76,77,78,79,80],"genetic in hypertensive kidney disease","salt intake in BP control and CKD progression","genetic in CKD","endogenous Ouabain as marker of AKI","protein intake restriction in CKD progression","hypertension in allogenic bone marrow transplantation","2024-05-11",{"date":83,"type":84},"2024-05-16","ACTUAL",{"date":86,"type":84},"2006-05-19",{"date":88,"type":62},"2041-05-19",{"name":5,"class":6},1]